Cargando…

Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma

The recent characterization of a group of non-MYC rearranged aggressive B-cell lymphomas, resembling Burkitt lymphoma (BL), characteristically harboring a telomeric 11q loss or combined 11q proximal gains/loss pattern has led to the introduction of the provisional entity of Burkitt-like lymphoma wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gebauer, Niklas, Witte, Hanno M., Merz, Hartmut, Oschlies, Ilske, Klapper, Wolfram, Caliebe, Almuth, Tharun, Lars, Spielmann, Malte, von Bubnoff, Nikolas, Feller, Alfred C., Murga Penas, Eva M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Stimulus Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153036/ https://www.ncbi.nlm.nih.gov/pubmed/34500469 http://dx.doi.org/10.1182/bloodadvances.2021004635

Ejemplares similares

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse
por: Samra, Bachar, et al.
Publicado: (2021)

Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation
por: Hertel, Nadine, et al.
Publicado: (2021)

Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients
por: Witte, Hanno M., et al.
Publicado: (2020)

Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways
por: Witte, Hanno M., et al.
Publicado: (2022)

Primary refractory plasmablastic lymphoma: A precision oncology approach
por: Witte, Hanno M., et al.
Publicado: (2023)

Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
por: Olschewski, Vito, et al.
Publicado: (2021)

Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm
por: Künstner, Axel, et al.
Publicado: (2022)

Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment
por: Teipel, Raphael, et al.
Publicado: (2022)

Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia
por: Möker, Paula, et al.
Publicado: (2022)

Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment
por: Lai, Catherine, et al.
Publicado: (2022)

Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity
por: Fernández-Rodríguez, Concepción, et al.
Publicado: (2022)

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2021)

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
por: Künstner, Axel, et al.
Publicado: (2021)

Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS
por: Syrykh, Charlotte, et al.
Publicado: (2021)

Day 30 SUV(max) predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy
por: Al Zaki, Ajlan, et al.
Publicado: (2022)

A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas
por: Munshi, Manit, et al.
Publicado: (2022)

Genomic insights into the pathogenesis of Epstein–Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing
por: Gebauer, Niklas, et al.
Publicado: (2021)

Indolent lymphoma with composite histology and simultaneous transformation at initial diagnosis exhibit clinical features similar to de novo diffuse large B-cell lymphoma
por: Witte, Hanno, et al.
Publicado: (2018)

Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age
por: Burkhardt, Birgit, et al.
Publicado: (2022)

Detection of EBV in reactive and neoplastic lymphoproliferations in adults—when and how?
por: Stuhlmann-Laeisz, Christiane, et al.
Publicado: (2014)

The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation
por: Witte, Hanno M., et al.
Publicado: (2020)

P1233: PRIMARY REFRACTORY PLASMABLASTIC LYMPHOMA: A PRECISION ONCOLOGY APPROACH
por: Witte, H., et al.
Publicado: (2022)

Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma
por: Au-Yeung, Rex K. H., et al.
Publicado: (2022)

Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma
por: Damm-Welk, Christine, et al.
Publicado: (2020)

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
por: Witte, Hanno M., et al.
Publicado: (2023)

Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma
por: Reutter, Katrin, et al.
Publicado: (2020)

Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection
por: Merz, Lauren E., et al.
Publicado: (2021)

Antibody-Negative Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS) in a Patient with Follicular Lymphoma Accompanied by an Excess of Peripheral Blood CD8+ Lymphocytes
por: Gambichler, Thilo, et al.
Publicado: (2022)

P1232: PRINCIPLES OF PRECISION ONCOLOGY IN PRIMARY REFRACTORY HIGH-GRADE B-CELL LYMPHOMA WITH MYC-, BCL2 AND/OR BCL6 REARRANGEMENTS (HGBL-DH/TH)
por: Witte, H., et al.
Publicado: (2022)

Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols
por: Rohde, Marius, et al.
Publicado: (2017)

Burkitt Lymphoma in the Mouse
por: Kovalchuk, Alexander L., et al.
Publicado: (2000)

Burkitt Lymphoma of the Duodenum
por: Matsueda, Katsunori, et al.
Publicado: (2017)

Burkitt's lymphoma of the mandible
por: Kuo, Ying-Shiung, et al.
Publicado: (2017)

Publisher Correction: Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma
por: Reutter, Katrin, et al.
Publicado: (2021)

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
por: Stroh, Jacob, et al.
Publicado: (2022)

Case Report: GNAQ- and SF3B1 Mutations in an Aggressive Case of Relapsing Uveal Ring Melanoma
por: Prasuhn, Michelle, et al.
Publicado: (2022)

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
por: Knörr, Fabian, et al.
Publicado: (2021)

Excretion of Immunoglobulins in Burkitt's Lymphoma
por: McFarlane, H., et al.
Publicado: (1970)

Pleural effusion in Burkitt's lymphoma.
por: Aderele, W. I., et al.
Publicado: (1975)

Cytology and Histochemistry of the Burkitt Lymphoma
por: Wright, D. H.
Publicado: (1963)

Cannot write session to /tmp/vufind_sessions/sess_48863dlulpn38oe8m0e9f6s8d3